Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Artificial cells

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    19 result(s) found for: Artificial cells. Displaying page 1 of 1.
    EudraCT Number: 2010-024290-40 Sponsor Protocol Number: CAH/Ulc/2010 Start Date*: 2012-12-04
    Sponsor Name:FUNDACIÓN PROGRESO Y SALUD
    Full Title: Multicenter clinical trial to evaluate the safety and feasibility of allogeneic tissue engineered product (human nanostructured artificial cornea) in patients with advanced corneal trophic ulcers r...
    Medical condition: trophic corneal ulcers refractaries to conventional treatment
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10048492 Corneal ulcer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2015-004233-27 Sponsor Protocol Number: RF-2013-02358757 Start Date*: 2016-06-23
    Sponsor Name:FONDAZIONE IRCCS CA' GRANDA OSPEDALE MAGGIORE POLICLINICO
    Full Title: Vitamin D Supplementation on Assisted Reproduction Technology (ART) outcomes: a randomized clinical controlled trial and an investigation of the involved biological mechanisms
    Medical condition: in vitro fertilization
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10056204 In vitro fertilisation PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-000982-19 Sponsor Protocol Number: IOBA-ImmunEyez_011-2018 Start Date*: 2019-12-11
    Sponsor Name:Instituto de Oftalmobiología Aplicada (IOBA)
    Full Title: A Phase IV Open-Label Clinical Trial to Evaluate the Efficacy of Ikervis® on Clinical Parameters and Molecular/Cellular Biomarkers in Dry Eye Patients with Severe Keratitis who have not improved de...
    Medical condition: Dry eye disease with severe keratitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004271-12 Sponsor Protocol Number: NGF0213 Start Date*: 2014-01-17
    Sponsor Name:Dompé s.p.a
    Full Title: An open-label study evaluating safety and efficacy of recombinant human nerve growth factor (rhNGF) eye drops at different doses in patients with Dry Eye
    Medical condition: Dry Eye syndrome is caused by either decreased tear production or increased tear film evaporation. Dry eye is a chronic inflammatory condition of the ocular surface with severe symptoms and visual ...
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004853 10013777 Dry eye syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001818-42 Sponsor Protocol Number: C41750/3100 Start Date*: 2016-04-14
    Sponsor Name:Teva Branded Pharmaceutical Products R&D, Inc.
    Full Title: A Double-blind, Randomized, Sham–procedure–controlled, Parallel-group Efficacy and Safety Study of Allogeneic Mesenchymal Precursor Cells (rexlemestrocel-L) in Patients with Chronic Heart Failure D...
    Medical condition: Chronic Heart Failure
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004849 10008908 Chronic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LV (Prematurely Ended) GB (Prematurely Ended) LT (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-002701-94 Sponsor Protocol Number: FUN-PIR-2020-01 Start Date*: 2021-08-13
    Sponsor Name:Fundación para la Gestión de la Investigación Biomédica de Cádiz
    Full Title: Pirfenidone for the reduction of pulmonary inflammatory and fibrogenic activity in patients with silicosis due to artificial stone and progressive massive fibrosis.
    Medical condition: progressive massive fibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10022117 - Injury, poisoning and procedural complications 10040678 Silicosis PT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10036805 Progressive massive fibrosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006227-31 Sponsor Protocol Number: 0881X1-4503 Start Date*: 2009-01-09
    Sponsor Name:Medical Faculty, Otto-von-Guericke-University Magdeburg
    Full Title: Inflammatory Topoproteome of Psoriasis under Etanercept Treatment
    Medical condition: Patients with a severe psoriasis will be treated with Enbrel (Etanercept) 2 x 50 mg s.c. per week over 12 weeks (n = 6 patients). The treatment follows rigorously the approved label of the drug. Th...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-007174-35 Sponsor Protocol Number: AM-KS-IV/5/07 Start Date*: Information not available in EudraCT
    Sponsor Name:Dr. Franz Köhler Chemie GmbH
    Full Title: Randomized, placebo-controlled phase-IV clinical trial for the application of physostigmine salicylate for an early post-operative restoration of vigilance and cognition after cardiopulmonary bypas...
    Medical condition: post-operative restoration of vigilance and cognition after cardiopulmonary bypass surgery
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066123 Cardiopulmonary bypass LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-003604-21 Sponsor Protocol Number: KT-IBA Start Date*: 2011-10-24
    Sponsor Name:Universitätsklinik für Innere Medizin IV, Medizinische Universität Innsbruck
    Full Title: The role of immunosuppressives in immunosenescence and immunotolerance in renal transplantation
    Medical condition: The impact of immunosuppressives on age-related changes of the immune system will be analyzed in patients after renal transplantation. Only patients at least one year after renal tranplantation and...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021428 - Immune system disorders 10062016 Immunosuppression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2007-000765-37 Sponsor Protocol Number: P-CKD-01 Start Date*: 2007-05-10
    Sponsor Name:Pharmacosmos A/S
    Full Title: A non-comparative open-label study of Iron Oligosaccharide in Chronic Kidney Disease patients with a need for parenteral iron
    Medical condition: Patients with Chronic kidney disease who are in pre-dialysis or undergoing dialysis (either Peritoneal Dialysis or Haemodialysis), who may be treated with erythropoeisis stimulating agents and have...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002062 Anaemia iron deficiency LLT
    9.1 10018875 Haemodialysis LLT
    9.1 10061105 Dialysis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) DK (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-001341-12 Sponsor Protocol Number: UV/AP/21 Start Date*: 2023-04-14
    Sponsor Name:Red Andaluza de Diseño y Traslación en Terapias Avanzadas - Fundación Pública Andaluza Progreso y Salud M.P.
    Full Title: Phase I-II, Multicenter, Randomized, Controlled, Proof of Concept Clinical Trial to determine feasibility, safety and efficacy of the use of Allogenic adipose-derived adult mesenchymal stem cells e...
    Medical condition: Venous ulcer
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10047259 Venous ulcer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018517-29 Sponsor Protocol Number: DMD-UHK-B1 Start Date*: 2010-02-22
    Sponsor Name:Medical Faculty, Otto-von-Guericke-University Magdeburg
    Full Title: Topoproteome-Analysis of Psoriasis under Fumarate-Treatment.
    Medical condition: Fumaderm initial / Fumaderm will be used in this CT completely "in-label", i.e. for the treatment of adult patients of both genders with moderate to severe plaque psoriasis in so far as a solely to...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-008009-23 Sponsor Protocol Number: CALMA Start Date*: 2009-03-23
    Sponsor Name:Servicio de Anestesia-Reanimación
    Full Title: Estudio aleatorizado, doble ciego y controlado sobre la eficacia de la albúmina y manitol en el cebado del sistema de circulación extracorpórea en cirugía cardiaca para reducir el sangrado postoper...
    Medical condition: Cardiac surgery with cardiopulmonary bypass. Postoperative bleeding and requirements of blood products
    Disease: Version SOC Term Classification Code Term Level
    9.1 10066123 Cardiopulmonary bypass LLT
    9.1 10036277 Postoperative bleeding LLT
    9.1 10005765 Blood product transfusion LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-004738-14 Sponsor Protocol Number: NanoGSkin-CB-2019 Start Date*: 2020-04-28
    Sponsor Name:Red Andaluza de Diseño y Traslación de Terapias Avanzadas - Fundación Pública Andaluza Progreso y Salud
    Full Title: PHASE II CLINICAL TRIAL EVALUATING THE SAFETY AND EFFICACY OF A TISSUE ENGINEERED AUTOLOGOUS SKIN SUBSTITUTE RECONSTRUCTIVE SURGERY FOR BASAL CELL CARCINOMA.
    Medical condition: Reconstructive skin surgery in basal cell cancer (Mohs surgery)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10004146 Basal cell carcinoma PT
    21.1 100000004865 10064974 Mohs micrographic surgery LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000256-35 Sponsor Protocol Number: CNPOBC2020 Start Date*: 2020-12-16
    Sponsor Name:Aalborg University Hospital
    Full Title: Intravenous immunoglobulin and prednisolone to women with unexplained recurrent pregnancy loss after assisted reproductive technology treatment: a randomised, double-blind, placebo-controlled trial
    Medical condition: Recurrent pregnancy loss after assisted reproductive technology treatment
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004868 10078356 Recurrent pregnancy loss LLT
    Population Age: Adults Gender: Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-001884-21 Sponsor Protocol Number: VTI-210 Start Date*: 2013-07-26
    Sponsor Name:VITAL THERAPIES INCORPORATED
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD IN SUBJECTS WITH SEVERE ACUTE ALCOHOLIC HEPATITIS (SAAH) AND LILLE SCORE FAILURE
    Medical condition: Severe Acute Alcoholic Hepatitis (sAAH)
    Disease: Version SOC Term Classification Code Term Level
    18.0 10019805 - Hepatobiliary disorders 10019755 Hepatitis chronic active PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-017192-26 Sponsor Protocol Number: BUILT_01 Start Date*: 2012-06-21
    Sponsor Name:Free State of Bavaria represented by Regensburg University represented by Regensburg University Hospital represented by
    Full Title: A 3-Armed Prospective Randomized Controlled, Open-Labeled Phase III Trial to Evaluate Late Introduction of Cyclosporine or Everolimus versus a 5-day Delay of Cyclosporine in Combination with MMF in...
    Medical condition: Liver transplantation, renal function, high MELD scores, infections, "bottom-up" immunosuppression
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021428 - Immune system disorders 10062016 Immunosuppression PT
    16.1 100000004857 10021523 Impaired renal function LLT
    16.1 100000004865 10024716 Liver transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2007-000535-26 Sponsor Protocol Number: P05133 Start Date*: 2007-06-04
    Sponsor Name:SCHERING-PLOUGH
    Full Title: SwiTching from etAnercept to iNfliximab in the treatment of moderate to severe psoriasis; a multi-center, open label trial evaluating the efficacy, tOlerance and safety (TANGO)
    Medical condition: Patients with moderate to severe psoriasi.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-005563-27 Sponsor Protocol Number: VTI-208 Start Date*: 2013-07-26
    Sponsor Name:Vital Therapies, Inc.
    Full Title: A RANDOMIZED, OPEN-LABEL, MULTICENTER, CONTROLLED STUDY TO ASSESS SAFETY AND EFFICACY OF ELAD IN SUBJECTS WITH ALCOHOL-INDUCED LIVER DECOMPENSATION (AILD)
    Medical condition: Alcohol-induced liver decompensation (AILD)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10019805 - Hepatobiliary disorders 10019755 Hepatitis chronic active PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 00:44:30 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA